Results of Operations and Financial Condition. On Augsut 4, 2026, Larimar Therapeutics, Inc. (the “Company”) announced its financial results and operational highlights for the second quarter ended June 30, 2026. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information furnished pursuant to this Item 2.02, including Exhibit 99.1 attached hereto, is intended to be furnished and shall not be deemed…

Results of Operations and Financial Condition. On May 14, 2026, Larimar Therapeutics, Inc. (the “ Company ”) announced its financial results and operational highlights for the first quarter ended March 31, 2026. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information furnished pursuant to this Item 2.02, including Exhibit 99.1 attached hereto, is intended to be furnished and shall not be deemed…

Results of Operations and Financial Condition. On March 19, 2026, Larimar Therapeutics, Inc. (the “ Company ”) announced its financial results and operational highlights for the fourth quarter of 2025 and for the year ended December 31, 2025. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information furnished pursuant to this Item 2.02, including Exhibit 99.1 attached hereto, is intended to be fur…

Entry into a Material Definitive Agreement. On February 25, 2026, Larimar Therapeutics, Inc. (the “ Company ”) entered into an underwriting agreement (the “ Underwriting Agreement ”) with J.P. Morgan Securities LLC and Guggenheim Securities, LLC, as representatives of the several underwriters named therein (the “ Underwriters ”), relating to the issuance and sale of an aggregate of 20,000,000 shares (the “ Firm Shares ”) of common stock, par value $0.001 per share (the “ Common Stock ”), of t…

Unregistered Sales of Equity Securities. On January 21, 2026, Larimar Therapeutics, Inc. (the “Company”) entered into an exchange agreement (the “Exchange Agreement”) with Blue Owl Healthcare Opportunities IV Public Investments LP (the “Stockholder”), pursuant to which the Stockholder exchanged 2,500,000 shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”), for 250,000 shares of Series A convertible preferred stock, a “toothless” preferred stock, par value $0.…

Results of Operations and Financial Condition. On January 12, 2026, Larimar Therapeutics, Inc. (the “ Company ”) disclosed in an updated slide presentation, posted on its website, that, as of December 31, 2025, the Company had approximately $136.9 million of cash, cash equivalents and marketable securities. The Company has not yet completed its quarter-end or year-end financial close processes for the quarter and year ended December 31, 2025. This unaudited, preliminary amount has been prepar…

Unregistered Sales of Equity Securities. On December 16, 2025, Larimar Therapeutics, Inc. (the “Company”) entered into an exchange agreement (the “Exchange Agreement”) with Blue Owl Healthcare Opportunities IV Public Investments LP (the “Stockholder”), pursuant to which the Stockholder exchanged 2,500,000 shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”), for 250,000 shares of newly designated Series A convertible preferred stock, a “toothless” preferred st…

Results of Operations and Financial Condition. On November 5, 2025, Larimar Therapeutics, Inc. (the “ Company ”) announced its financial results and operational highlights for the third quarter ended September 30, 2025. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information furnished pursuant to this Item 2.02, including Exhibit 99.1 attached hereto, is intended to be furnished and shall not be…

Results of Operations and Financial Condition. On August 14, 2025, Larimar Therapeutics, Inc. (the “ Company ”) announced its financial results and operational highlights for the second quarter ended June 30, 2025. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information furnished pursuant to this Item 2.02, including Exhibit 99.1 attached hereto, is intended to be furnished and shall not be deem…

Entry into a Material Definitive Agreement. On July 29, 2025, Larimar Therapeutics, Inc. (the “ Company ”) entered into an underwriting agreement (the “ Underwriting Agreement ”) with Leerink Partners LLC and Guggenheim Securities, LLC, as representatives of the several underwriters named therein (the “ Underwriters ”), relating to the issuance and sale of an aggregate of 18,750,000 shares (the “ Firm Shares ”) of common stock, par value $0.001 per share (the “ Common Stock ”), of the Company…

Results of Operations and Financial Condition. On July 29, 2025, Larimar Therapeutics, Inc. (the “ Company ”) announced in a preliminary prospectus supplement filed pursuant to Rule 424(b)(5) of the Securities Act of 1933, as amended (the “ Securities Act ”), that, as of June 30, 2025, the Company had approximately $138.5 million of cash, cash equivalents and marketable securities. The Company has not yet completed its quarter-end financial close processes for the quarter ended June 30, 2025.…

Results of Operations and Financial Condition. On April 30, 2025, Larimar Therapeutics, Inc. announced its financial results and operational highlights for the first quarter ended March 31, 2025. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information furnished pursuant to this Item 2.02, including Exhibit 99.1 attached hereto, is intended to be furnished and shall not be deemed “filed” for purp…

Results of Operations and Financial Condition. On March 24, 2025, Larimar Therapeutics, Inc. (the “ Company ”) announced its financial results and operational highlights for the fourth quarter of 2024 and for the year ended December 31, 2024. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information furnished pursuant to this Item 2.02, including Exhibit 99.1 attached hereto, is intended to be fur…

The filing describes the grant of performance-based restricted stock units to certain officers, which is a compensatory arrangement and not a management change.

Results of Operations and Financial Condition. On October 30, 2024, Larimar Therapeutics, Inc. (the “ Company ”) announced its financial results and operational highlights for the third quarter ended September 30, 2024. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information furnished pursuant to this Item 2.02, including Exhibit 99.1 attached hereto, is intended to be furnished and shall not be…

Results of Operations and Financial Condition. On August 7, 2024, Larimar Therapeutics, Inc. (the “ Company ”) announced its financial results and operational highlights for the second quarter ended June 30, 2024. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information furnished pursuant to this Item 2.02, including Exhibit 99.1 attached hereto, is intended to be furnished and shall not be deeme…

Results of Operations and Financial Condition. On May 9, 2024, Larimar Therapeutics, Inc. (the “ Company ”) announced its financial results and operational highlights for the first quarter ended March 31, 2024. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information furnished pursuant to this Item 2.02, including Exhibit 99.1 attached hereto, is intended to be furnished and shall not be deemed “…

Results of Operations and Financial Condition. On March 14, 2024, Larimar Therapeutics, Inc. announced its financial results and operational highlights for the fourth quarter of 2023 and for the year ended December 31, 2023. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information furnished pursuant to this Item 2.02, including Exhibit 99.1 attached hereto, is intended to be furnished and shall n…

Entry into a Material Definitive Agreement. On February 14, 2024, Larimar Therapeutics, Inc. (the “ Company ”) entered into an underwriting agreement (the “ Underwriting Agreement ”) with Leerink Partners LLC, Citigroup Global Markets Inc. and Guggenheim Securities, LLC, as representatives of the several underwriters named therein (the “ Underwriters ”), relating to an underwritten public offering (the “ Offering ”) of 17,162,472 shares (the “ Shares ”) of the common stock, par value $0.001 p…

Termination of a Material Definitive Agreement. On February 13, 2024, Larimar Therapeutics, Inc. (the “ Company ”) gave notice to terminate the Sales Agreement that the Company entered into with Guggenheim Securities, LLC on November 10, 2022 (the “ Sales Agreement ”). Termination of the Sales Agreement was effective February 13, 2024. Under the Sales Agreement, the Company was permitted to offer and sell, from time to time at its sole discretion, shares of its common stock, par value $0.001…

Results of Operations and Financial Condition. On February 12, 2024, Larimar Therapeutics, Inc. (the “ Company ”) announced that, as of December 31, 2023, the Company had approximately $86.8 million of cash, cash equivalents and marketable securities. This unaudited, preliminary amount has been prepared by and is the responsibility of management. This amount is based upon information available to management as of the date of this Current Report on Form 8-K and subject to completion of financi…